Alefacept

Drug Profile

Alefacept

Alternative Names: Amevive; ASP 0485; BG 9273; BG 9712; Human LFA-3/IgG fusion protein; LFA 3 TIP; LFA-3(92)IgG; Recombinant LFA-3/IgG1 human fusion protein

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator University of Michigan Medical School
  • Developer Astellas Pharma
  • Class Antipsoriatics; Recombinant fusion proteins
  • Mechanism of Action CD2 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • Discontinued Psoriatic arthritis; Transplant rejection

Most Recent Events

  • 15 Mar 2012 Astellas Pharma completes its Phase-II trial for Psoriasis in USA, Bulgaria and Latvia (NCT00808223)
  • 01 Jan 2012 Astellas Pharma completes enrolment in its phase II trial for Psoriasis in USA, Bulgaria and Latvia (NCT00808223)
  • 07 Feb 2011 Discontinued - Phase-II for Transplant rejection in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top